BioSante Pharmaceuticals Featured in the First Flaherty Special Situations.Company's LibiGel Highlighted as Pioneering the Treatment of Female Sexual Dysfunction sexual dysfunction Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. in the U.S. WEST HARRISON, N.Y. -- BioSante Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BPAX) was recently highlighted in an article that appeared in the December 18, 2007 first issue of Flaherty Special Situations Newsletter published by Flaherty Financial News Inc. The piece examined the company's Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical development of LibiGel and its ongoing corporate strategy. Titled, "Betting on Sexual Satisfaction for 2008," the newsletter article addresses that there are three products on the market including Viagra that enhance sexual satisfaction for U.S. men, but not one for women. BioSante's ambitious goal: First to market in the U.S. treatment with a product to alleviate Female Sexual Dysfunction -a huge $2 billion unmet medical need. To read the article, please visit our website at www.flahertyfinancialnews.com and click on the newsletter archive button. Then click on the Flaherty Special Situations report on BPAX. To receive future issues of Flaherty Special Situations or Flaherty Financial News Newsletters simply opt-in as a reader. You can opt out at any time. We thank our old readers for their loyalty and hope many new ones will join our financial family. For accredited investors only, those who want to sign up and have a badge waiting for our upcoming January 22, 2008 FlahertyFinancialNews/Wall Street Research Small Cap Conference III , please visit the separate website www.smallcapconference.org and log on to attend. About Flaherty Financial News Inc. Flaherty Financial News Inc. (FFN FFN Fetal Fibronectin FFN Fédération Francaise de Naturisme FFN Fanfiction.net (fan fiction archive) FFN Full Frontal Nudity (movie reference) FFN Fleet Flash Net FFN Family Financial Network ) is the publisher of totally-electronic coverage of the neglected micro-and small-cap markets. It was launched in February 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc. , together with his son Brian, who serves as President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years until it was sold in September 2006, Bob was also Editor-in-Chief of Equities Special Situations, which had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest Hulbert Financial Digest A monthly newsletter devoted to information about investment advisory letters. The publication includes a top-five ranking of advisory letters during short and extended periods, along with commentary and detailed . Previously, he was an award-winning Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all time record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude cum lau·de adv. & adj. With honor. Used to express academic distinction: graduated cum laude; 25 cum laude graduates. graduate of Harvard College Harvard College is the undergraduate section and oldest school of Harvard University, founded in 1636 by the Massachusetts Legislature. The College is instructed by the Faculty of Arts and Sciences, which also instructs the Harvard Graduate School of Arts and Sciences. in economics and also has an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration with a Distinction in Finance from Harvard Business School Harvard Business School, officially named the Harvard Business School: George F. Baker Foundation, and also known as HBS, is one of the graduate schools of Harvard University. . Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement and Disclosure of Conflicts Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of l933m as amended, and Section 21E of the Securities Act of l934, as amended. Such statements include declarations regarding the intent, belief or current expectations of BioSante and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. , the successful completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, especially Procter & Gamble, product pricing and third party reimbursement, and other factors which are included in BioSante's most recent annual report and other reports filed with the Securities and Exchange Commission. In the interests of full disclosure, we note this conflict of interest: BioSante Pharmaceutical Inc. paid $6,500 to present at our August 14, 2007 FlahertyFinancialNews/WallStreet Research Small Cap Conference II and also paid an additional $12,500 for extra distribution of this December 18, 2007 Flaherty Special Situation and also the Flaherty Financial News issue of November 27, 2007 which also featured BioSante. No one at Flaherty Financial News Inc. is a shareholder of BioSante and our editorial trading policy forbids buying or selling a featured stock until ten business days after the issue is first released. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion